Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.66 |
| ▸ | PIK3CB | P42338 | 20/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.66 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | HCK | P08631 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 1/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.66 |
| ▸ | MTOR | P42345 | 1/20 | 0.66 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.66 |
| ▸ | PRKDC | P78527 | 1/20 | 0.66 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582545 | 0.87 | PIK3CD (0.62) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL17582568 | 0.84 | PIK3CD (0.75) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL17582615 | 0.81 | PIK3CD (0.68) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL17582540 | 0.81 | PIK3CD (0.82) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL2464877 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL21323771 | 0.80 | PIK3CD (0.44) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL17582609 | 0.78 | PIK3CD (0.38) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL129487 | 0.77 | PIK3CD (0.72) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL17582561 | 0.77 | PIK3CD (0.69) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 | |
| SCHEMBL19209426 | 0.76 | PIK3CD (0.65) | PIK3CDPIK3CBPIK3CAPIK3CGABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191491-B1 | PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-04 | — | — | EP | claimed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | claimed |
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-03-17 | — | — | US | claimed |
| EP-3191491-B1 | PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| EP-3191491-B1 | PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | disclosed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | disclosed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | disclosed |
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-03-17 | — | — | US | disclosed |
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIP4K2B, PIP5K1B, PIK3CA | PIK3CD 9/4885PIK3CB 5/4885PIK3CA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.